Biogen Hid Issues With Alzheimer's Drug, Investor Suit Claims
Biogen was hit with a proposed class action Monday from investors whose shares plummeted after a controversial new Alzheimer's drug failed to deliver the financial gains they expected....To view the full article, register now.
Already a subscriber? Click here to view full article